Economic burden in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with or without brain metastases, receiving first-line ALK inhibitors

INTRODUCTION: This observational study describes the real-world economic burden in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) receiving a first-line ALK inhibitor, and the economic impact of brain metastases (BM). METHODS: Administrative claims data (T...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yanyu, Ren, Kaili, Wan, Yin, Lin, Huamao M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540485/
https://www.ncbi.nlm.nih.gov/pubmed/36131505
http://dx.doi.org/10.1177/10781552221126174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540485/
https://www.ncbi.nlm.nih.gov/pubmed/36131505
http://dx.doi.org/10.1177/10781552221126174

Ejemplares similares